NEW YORK, June 20, 2013 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: <\/p>\n
Personalized Medicine Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment http:\/\/www.reportlinker.com\/p01361264\/Personalized-Medicine-Market---A-Strategic-Analysis-of-Industry-Trends-Technologies-Participants-and-Environment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics<\/a><\/p>\n This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 239 tables & figures. <\/p>\n The personalized medicine (global) market is presented as follows: <\/p>\n By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, CELERA, MYRIAD) By Geography (US, UK, EU) By Segment (Targeted therapeutics, Esoteric tests, Esoteric lab services) By Sub-market (Companion diagnostics & therapeutic, nutrition & wellness, medical technology, pharmacogenomics, consumer genomics)<\/p>\n A wealth of financial data & business strategy information is provided including: <\/p>\n Up-to-date company financials, sales & revenue figures Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies Business Model Strategies for Providers. Provider Systems and Academic Medical Centres Business Model Strategies for Payers & Governments Private and Public Funding and Personalized Medicine Reimbursement Revisions to Current Payment Systems and intellectual property How to Gain Market Penetration in the EU Cost-effectiveness and Business Value of Personalized Medicine Consumer genomics and POC market Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) Comprehensive account of company product portfolios & kits<\/p>\n SWOT, Economic & Regulatory Environment specifics include: <\/p>\n Key strengths, weaknesses and threats influencing leading player position within the market Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing) Top fastest growing market segments and emerging opportunities Top pharmaceutical companies within the IPM by market share and revenue Comprehensive product portfolios, R&D activity and pipeline therapeutics M&A activity and future strategies of top personalized medicine pharmacos Personalized Medicine Regulation (UK, Germany, France, Spain, Italy) CE-marked Personalized Medicine\/Diagnostic Tests FDA Advances in Personalized Medicine Regulation<\/p>\n This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. <\/p>\n <\/p>\n View post:<\/p>\n Personalized Medicine Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" NEW YORK, June 20, 2013 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Personalized Medicine Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment http:\/\/www.reportlinker.com\/p01361264\/Personalized-Medicine-Market---A-Strategic-Analysis-of-Industry-Trends-Technologies-Participants-and-Environment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics<\/a> This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 239 tables & figures. The personalized medicine (global) market is presented as follows: By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, CELERA, MYRIAD) By Geography (US, UK, EU) By Segment (Targeted therapeutics, Esoteric tests, Esoteric lab services) By Sub-market (Companion diagnostics & therapeutic, nutrition & wellness, medical technology, pharmacogenomics, consumer genomics) A wealth of financial data & business strategy information is provided including: Up-to-date company financials, sales & revenue figures Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies Business Model Strategies for Providers. Continue reading